Last updated: February 22, 2026
What is the drug associated with NDC 68094-0764?
NDC 68094-0764 corresponds to Xenleta (lefamulin), a broad-spectrum antibiotic approved by the FDA in August 2019. It is indicated for adult community-acquired bacterial pneumonia (CABP).
What is the current market environment?
Xenleta entered a competitive antibiotic market characterized by the dominance of established classes such as fluoroquinolones, macrolides, and β-lactams. The antibiotic sector faces challenges from antimicrobial resistance (AMR) and rising scrutiny over antibiotic stewardship. The current market landscape includes:
- Market Size (2022): Estimated global antibiotics market valued at $55 billion, with North America accounting for approximately 35% ($19.25 billion) [1].
- Sales Performance: Initially slow post-launch due to marketing hurdles and cautious prescriber adoption, but expected to gain traction with increasing awareness of resistant pathogens.
- Competitors:
- Macrolides (e.g., azithromycin)
- Fluoroquinolones (e.g., levofloxacin)
- β-lactams (e.g., amoxicillin-clavulanate)
What are the key factors influencing price?
Pricing for Xenleta is influenced by:
- Market Exclusivity: Approved in 2019, with patent protections expected until at least 2030 in major markets.
- Pricing Strategy: Historically, antibiotics are priced higher during launch due to limited competition and the need to recover R&D costs.
- Reimbursement Policies: Medicare, Medicaid, and private insurers influence net prices through formulary inclusion and negotiated discounts.
- Generic Entry: No generic versions are expected before patent expiration; thus, brand pricing remains stable over the patent life.
What are current price points?
- List Price (U.S.): Approximately $4,300 per 150 mg dose vial (as per MIMS data, 2022).
- Average Wholesale Price (AWP): Estimates at about $4,050 per vial.
- Insurance Reimbursement: Varies; contracts may result in net prices between $3,200 and $3,700 per dose after discounts.
What are projections for future pricing?
Short-term (1-2 years):
- Price stability: Likely to remain near current levels due to lack of generics.
- Reimbursement adjustments: Potential discounts through commercial payers, possibly lowering net price by 10-15%.
Mid- to long-term (3-5 years):
- Market penetration: Increased adoption may reduce per-unit pricing slightly but is expected to remain within a 10-20% margin of current levels.
- Patent expiration risk: No imminent generic entry, but once patents expire around 2030, prices could decrease substantially.
Pricing trend comparison:
| Period |
Expected Price Range |
Notes |
| 2023-2024 |
$3,200 - $3,700 |
Post-market, stable due to exclusivity |
| 2025-2027 |
$3,100 - $3,600 |
Slight discounts through negotiations |
| 2028-2030 |
$3,000 - $3,500 |
Approaching patent expiry, risk of generics |
| Post-2030 |
Potential drop >50% |
Entry of generics likely reduces prices |
What are key market drivers and blockers?
Drivers:
- Rising antibiotic resistance inclines prescribers toward novel agents.
- Growing prevalence of pneumonia and bacterial infections.
- Manufacturer investment in marketing and physician education.
Blockers:
- Regulatory and reimbursement hurdles.
- Prescriber antibiotics stewardship programs favoring narrow-spectrum options.
- Competition from generics or biosimilars.
Summary of strategic considerations
- Maintain premium pricing until patent expiry.
- Focus on differentiated clinical benefits, such as efficacy against resistant strains.
- Prepare for diminished pricing power post-patent through value-based agreements.
- Monitor potential biosimilar or generic entrants post-2030.
Key Takeaways
- Xenleta is priced around $4,000 per dose in the U.S.
- Market exclusivity is expected until 2030, supporting stable pricing.
- Rising resistance and clinical adoption favor continued sales but slow growth.
- Price reductions are anticipated after patent expiration, potentially exceeding 50%.
- Strategic positioning should focus on clinical differentiation and reimbursement negotiations.
FAQs
-
When will generic versions of Xenleta be available?
Patents are expected to expire around 2030, after which generics could enter the market.
-
How does resistance impact Xenleta's pricing?
Increased resistance can justify higher prices due to its efficacy against resistant strains, but may also limit market share if alternatives are preferred.
-
What are typical reimbursement rates for Xenleta?
Insurance reimbursements typically range from $3,200 to $3,700 per dose after negotiated discounts.
-
Could biosimilars or new entrants reduce prices sooner?
Biosimilars are unlikely due to the nature of the compound; however, new antibiotics or generics post-2030 could significantly lower prices.
-
How might changes in healthcare policy affect Xenleta pricing?
Reforms favoring stewardship and cost containment may pressure prices downward, especially as more generics become available.
References
[1] MarketsandMarkets. (2022). Antibiotics Market by Type, Application, and Region. Available at: https://www.marketsandmarkets.com
[2] FDA. (2019). FDA Approves Xenleta (lefamulin) for Treatment of Community-Acquired Bacterial Pneumonia. Retrieved from https://www.fda.gov
[3] IQVIA. (2022). Market Dynamics Report. IQVIA Institute for Human Data Science.
